Endologix (NASDAQ:ELGX) released its quarterly earnings results on Wednesday. The medical instruments supplier reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.13, Bloomberg Earnings reports. The business had revenue of $44.00 million for the quarter, compared to analyst estimates of $44.91 million. Endologix had a negative net margin of 41.60% and a negative return on equity of 52.18%. The company’s quarterly revenue was down 7.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.30) earnings per share.
Shares of Endologix (NASDAQ:ELGX) traded up $0.05 during midday trading on Thursday, reaching $4.38. 598,800 shares of the company were exchanged, compared to its average volume of 791,865. Endologix has a 1 year low of $3.75 and a 1 year high of $7.66. The firm has a market capitalization of $361.36, a price-to-earnings ratio of -4.27 and a beta of 0.42. The company has a debt-to-equity ratio of 2.61, a quick ratio of 2.11 and a current ratio of 2.90.
ELGX has been the topic of several research reports. JPMorgan Chase & Co. lowered shares of Endologix from a “neutral” rating to an “underweight” rating in a research report on Tuesday, January 2nd. Royal Bank of Canada lowered their price target on shares of Endologix from $5.00 to $4.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 8th. BidaskClub lowered shares of Endologix from a “buy” rating to a “hold” rating in a research report on Friday, December 15th. Stifel Nicolaus lowered their price target on shares of Endologix from $6.00 to $5.50 and set a “hold” rating on the stock in a research report on Wednesday, November 8th. Finally, ValuEngine lowered shares of Endologix from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company’s stock. Endologix currently has a consensus rating of “Hold” and a consensus target price of $5.41.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.